Table 2.
Summary of statistical analysis of the change from placebo in primary endpoints at day 28
| Treatment | Statistics | Mean blood flow velocity MCA (cm s−1) | Platelet closure time (s) | Central foveal thickness right eye (μm) | Central foveal thickness left eye (μm) |
|---|---|---|---|---|---|
| Reference value* | 11.32 | 22.60 | 35.21 | 34.62 | |
| Fingolimod 0.5 mg | n | 30 | 30 | 30 | 30 |
| LS mean | 53.23 | 120.94 | 174.00 | 176.29 | |
| Difference (95% CI) | 0.58 (−2.83, 3.99) | −3.03 (−11.99, 5.94) | −3.58 (−10.28, 3.11) | 3.04 (−1.66, 7.75) | |
| Conclusion | Non-inferior | Non-inferior | Non-inferior | Non-inferior | |
| Fingolimod 1.25 mg | n | 29 | 29 | 29 | 29 |
| LS mean | 55.25 | 119.75 | 178.66 | 177.53 | |
| Difference (95% CI) | 2.60 (−0.83, 6.03) | −4.22 (−13.31, 4.88) | 1.08 (−5.65, 7.81) | 4.29 (−0.41, 8.99) | |
| Conclusion | Non-inferior | Non-inferior | Non-inferior | Non-inferior |
*
Reference value: 20% of mean baseline value. CI, confidence interval; LS mean, least square mean; MCA, middle cerebral artery.